Author

T. P. Cripe

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Organism:human· 1

Frequent Co-Authors

E. R. Mardis· 2 shared P. Rajappa· 2 shared A. C. Gross· 1 shared A. Canella· 1 shared A. Haffey· 1 shared A. M. Glaspell· 1 shared C. Schmitt· 1 shared C.-Y. Chen· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. R. Mardis

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone Sarcoma

E. M. Ringwalt, M. A. Currier, A. M. Glaspell, C.-Y. Chen, M. V. Cannon, M. Cam, A. C. Gross, M. Gust, P.-Y. Wang, L. Boon, L. E. Biederman, E. Schwarz, P. Rajappa, D. A. Lee, E. R. Mardis, , T. P. Cripe

This study shows trabectedin enhances oncolytic virotherapy by reducing anti-viral barriers and boosting immune-mediated tumor regression in preclinical models.

bioRxiv · Mar 2, 2024Cancer Biology

Genetically modified IL-2 bone marrow-derived myeloid cells reprogram the glioma immunosuppressive tumormicroenvironment

A. Canella, M. Nazzaro, S. Rajendran, C. Schmitt, A. Haffey, G. Nigita, D. Thomas, H. Wrightnour, P. Fadda, E. R. Mardis, T. P. Cripe, P. Rajappa

This study shows that genetically modified myeloid cells releasing IL-2 can reprogram the glioma tumor microenvironment to enhance anti-tumor immunity in a mouse model.

bioRxiv · Oct 19, 2022 · PreprintCancer Biology